PKM2-IN-1
(Synonyms: Compound 3K, MDK4882, PKM2-IN-1, Pyruvate Kinase M2 Inhibitor) 目录号 : GC32738
PKM2-IN-1 是一种丙酮酸激酶 M2 (PKM2) 抑制剂，IC50 为 2.95 μM。
Cas No.:94164-88-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Mesencgymal stem cells(MSCs) |
|
Preparation Method |
PKM2-IN-1 (10 mM) was dissolved in dimethyl sulfoxide (DMSO) and stored at -80℃ for subsequent experiments. MSCs were seeded into a 12-well plate and induced in adipogenic medium containing PKM2-IN-1 (10 μM). |
|
Reaction Conditions |
PKM2-IN-1 10 μM |
|
Applications |
Increasing the concentration of PKM2-IN-1 gradually promoted adipogenesis confirming the role of PKM2 activity in the TRAF4-mediated inhibition of adipogenic differentiation, 10 μM PKM2-IN-1 increased adipogenesis in the TRAF4-overexpressing group |
| Animal experiment [2]: | |
|
Animal models |
BALB/c nude mice subcutaneously injected with SK-OV-3 cells |
|
Preparation Method |
Once the tumor reached 200 cm3, the mice were randomly divided into two groups (n = 5 per group). PKM2-IN-1 (5 mg/kg body weight) dissolved in 1 ml of solvent was administered orally every 2 days for 31 days. |
|
Dosage form |
5 mg/kg PKM2-IN-1 orally every 2 days for 31 days |
|
Applications |
PKM2-IN-1 treatment markedly decreased the tumor volume and tumor weight, compared with the control group. Meanwhile, no significant weight reduction was detected in the mouse treated with PKM2-IN-1, suggesting that PKM2-IN-1 did not cause any major organ toxicity. Thus, use of specific PKM2 inhibitors to block the glycolytic pathway and target cancer cell metabolism represents a promising therapeutic approach for treating PKM2-overexpressing ovarian cancer. |
|
References: [1]. Cen S, Li J, et,al. TRAF4 acts as a fate checkpoint to regulate the adipogenic differentiation of MSCs by activating PKM2. EBioMedicine. 2020 Apr;54:102722. doi: 10.1016/j.ebiom.2020.102722. PMID: 32268273; PMCID: PMC7191261. [2]. Park JH, Kundu A, et,al. Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells. Int J Biol Sci. 2021 May 5;17(8):1895-1908. doi: 10.7150/ijbs.59855. PMID: 34131394; PMCID: PMC8193271. |
|
PKM2-IN-1 is a pyruvate kinase M2 (PKM2) inhibitor with an IC50 of 2.95μM[5].
In MSCs, Increasing the concentration of PKM2-IN gradually promoted adipogenesis confirming the role of PKM2 activity in the TRAF4-mediated inhibition of adipogenic differentiation, 10 μM PKM2-IN increased adipogenesis in the TRAF4-overexpressing group[1]. In the Huh7 cell line, PKM2-IN-1 inhibited CCL20-mediated PKM2 expression and nuclear localization without affecting the phosphorylation of ERK1/2. Furthermore, PKM2-IN-1 inhibited CCL20-mediated aerobic glycolysis and reduced the ability of Huh7 cells to consume glucose and produce lactate and ATP[3].PKM2-IN-1 decreased lactate product and glucose uptake in Eca109 and Ec9706 ?cells[4].PKM2-IN-1 can induce cytotoxicity in HNSCC cells without affecting their glycolysis rate or oxygen consumption[7].PKM2-IN-1 highly increased late apoptosis in U87MG glioma cells without G2-phase arrest[8]
In mice, PKM2-IN-1 treatment markedly decreased the tumor volume and tumor weight, compared with the control group. Meanwhile, no significant weight reduction was detected in the mouse treated with PKM2-IN-1, suggesting that PKM2-IN-1 did not cause any major organ toxicity. Thus, use of specific PKM2 inhibitors to block the glycolytic pathway and target cancer cell metabolism represents a promising therapeutic approach for treating PKM2-overexpressing ovarian cancer[6].In hearts of 7-day-old mice, PKM2-specific inhibitor PKM2-IN-1 significantly blocked the proliferation of cardiomyocytes in HRR groups, indicating HRR-induced proliferation of cardiomyocytes was fully abolished by PKM2-IN-1[2]
References:
[1]: Cen S, Li J, et,al. TRAF4 acts as a fate checkpoint to regulate the adipogenic differentiation of MSCs by activating PKM2. EBioMedicine. 2020 Apr;54:102722. doi: 10.1016/j.ebiom.2020.102722. PMID: 32268273; PMCID: PMC7191261.
[2]: Tan J, Yang M, et,al. Moderate heart rate reduction promotes cardiac regeneration through stimulation of the metabolic pattern switch. Cell Rep. 2022 Mar 8;38(10):110468. doi: 10.1016/j.celrep.2022.110468. PMID: 35263588.
[3]: Yuan Q, Zhang J, et,al. MyD88 in myofibroblasts regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation. J Pathol. 2022 Apr;256(4):414-426. doi: 10.1002/path.5856. Epub 2022 Jan 27. PMID: 34927243.
[4]: Li S, Huang P, et,al. Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2. Eur J Pharmacol. 2019 Jul 5;854:232-239. doi: 10.1016/j.ejphar.2019.04.018. Epub 2019 Apr 17. PMID: 31004604.
[5]: Ning X, Qi H, et,al. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase. Eur J Med Chem. 2017 Sep 29;138:343-352. doi: 10.1016/j.ejmech.2017.06.064. Epub 2017 Jun 29. PMID: 28688274.
[6]: Park JH, Kundu A, et,al. Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells. Int J Biol Sci. 2021 May 5;17(8):1895-1908. doi: 10.7150/ijbs.59855. PMID: 34131394; PMCID: PMC8193271.
[7]:Boschert V, Teusch J, et,al. PKM2 Modulation in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2022 Jan 11;23(2):775. doi: 10.3390/ijms23020775. PMID: 35054968; PMCID: PMC8775697.
[8]:Park JH, Lee JS, et,al. PKM2 Is Overexpressed in Glioma Tissues, and Its Inhibition Highly Increases Late Apoptosis in U87MG Cells With Low-density Specificity. In Vivo. 2022 Mar-Apr;36(2):694-703. doi: 10.21873/invivo.12755. PMID: 35241524; PMCID: PMC8931915.
PKM2-IN-1 是一种丙酮酸激酶 M2 (PKM2) 抑制剂，IC50 为 2.95μM[5]。
在 MSC 中，增加 PKM2-IN 的浓度逐渐促进脂肪生成，证实了 PKM2 活性在 TRAF4 介导的脂肪生成分化抑制中的作用，10 μM PKM2-IN 增加了 TRAF4 过表达组的脂肪生成[1 ]。在 Huh7 细胞系中，PKM2-IN-1 抑制 CCL20 介导的 PKM2 表达和核定位，而不影响 ERK1/2 的磷酸化。此外，PKM2-IN-1 抑制 CCL20 介导的有氧糖酵解并降低 Huh7 细胞消耗葡萄糖和产生乳酸和 ATP 的能力[3]。PKM2-IN-1 减少乳酸产物和葡萄糖摄取在 Eca109 和 Ec9706 细胞[4].PKM2-IN-1 可在 HNSCC 细胞中诱导细胞毒性而不影响其糖酵解速率或耗氧量[7].PKM2-IN- 1 无 G2 期阻滞的 U87MG 神经胶质瘤细胞晚期凋亡显着增加[8]
在小鼠中，与对照组相比，PKM2-IN-1 治疗显着降低了肿瘤体积和肿瘤重量。同时，在用 PKM2-IN-1 处理的小鼠中未检测到明显的体重减轻，表明 PKM2-IN-1 不会引起任何主要器官毒性。因此，使用特定的 PKM2 抑制剂来阻断糖酵解途径和靶向癌细胞代谢是治疗 PKM2 过表达卵巢癌的一种很有前途的治疗方法[6]。在 7 日龄小鼠的心脏中， PKM2 特异性抑制剂 PKM2-IN-1 显着阻断 HRR 组心肌细胞的增殖，表明 PKM2-IN-1 完全消除了 HRR 诱导的心肌细胞增殖[2]
| Cas No. | 94164-88-2 | SDF | |
| 别名 | Compound 3K, MDK4882, PKM2-IN-1, Pyruvate Kinase M2 Inhibitor | ||
| Canonical SMILES | S=C(N1CCCCC1)SCC(C2=O)=C(C)C(C3=C2C=CC=C3)=O | ||
| 分子式 | C18H19NO2S2 | 分子量 | 345.48 |
| 溶解度 | DMSO : 5.56 mg/mL (16.09 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8945 mL | 14.4726 mL | 28.9452 mL |
| 5 mM | 0.5789 mL | 2.8945 mL | 5.789 mL |
| 10 mM | 0.2895 mL | 1.4473 mL | 2.8945 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。